The Jo-1 antibody system in myositis: relationships to clinical features and HLA.

Antibodies to Jo-1, a saline extractable nuclear antigen, were found in 11/47 (23%) patients with myositis and in 0/35 controls with systemic lupus erythematosus or progressive systemic sclerosis (p less than or equal to 0.01). Within myositis subgroups, anti-Jo-1 occurred in 6/20 (30%) with polymyositis, 2/16 (13%) with dermatomyositis and 3/7 (43%) with overlap. There was an association between Jo-1 antibodies and HLA-DR3, irrespective of race or clinical subgroups (p less than or equal to 0.05). All anti-Jo-1 positive patients had either HLA-DR3, HLA-DRW6 or both (p less than or equal to 0.01). Thus, this antibody system might arise as a result of an aberrant immune response mediated at or near HLA-D in patients with myositis.
AuthorsF C Arnett, T J Hirsch, W B Bias, M Nishikai, M Reichlin
JournalThe Journal of rheumatology (J Rheumatol) 1981 Nov-Dec Vol. 8 Issue 6 Pg. 925-30 ISSN: 0315-162X [Print] CANADA
PMID6977032 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Antibodies, Antinuclear
  • HLA Antigens
  • HLA-DR Antigens
  • Histocompatibility Antigens Class II
  • Antibodies, Antinuclear (analysis)
  • Female
  • HLA Antigens (analysis, immunology)
  • HLA-DR Antigens
  • Histocompatibility Antigens Class II
  • Humans
  • Myositis (immunology, physiopathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: